article thumbnail

7 “Make or Break” Factors for Emerging Biopharma Companies

Fierce BioTech

7 “Make or Break” Factors for Emerging Biopharma Companies This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.

article thumbnail

A Closer Look At Our On-Site Compounding Pharmacies

Alta Sciences

Regulatory Excellence - Licenses for Schedule I through IV drug substances. BOOK A VISIT You may also be interested in the following webpages:​​​ Clinical Research Services Pharmaceutical CDMO and Contract Manufacturing Services DID YOU KNOW? Electronic security access to the pharmacy and video monitoring. -

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Twist Bioscience Announces Pricing of a $300 Million Upsized Public Offering of Common Stock

The Pharma Data

Twist may also use a portion of the net proceeds to in-license, acquire or invest in complementary businesses or products. are acting as joint book-running managers. Morgan Securities LLC, Goldman Sachs & Co. LLC, Cowen and Company, LLC and Evercore Group L.L.C. Baird & Co. Incorporated is acting as lead manager.

DNA 52
article thumbnail

Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer

The Pharma Data

As part of this role he built innovative, high-performing development teams and managed the Regeneron’s regulatory filings, interactions with regulatory agencies, product launches, and business development and licensing activities across its product portfolio. Dr. Graham earned an M.D., from the University of Adelaide in Australia.

Science 52
article thumbnail

FDA Knows Its Own Strength—and It Includes Concentration

FDA Law Blog: Biosimilars

On February 23—the same day that the Agency licensed SIMLANDI (adalimumab-ryvk) Injection , the first interchangeable high-concentration, citrate-free biosimilar to HUMIRA, and that qualifies for First Interchangeable Exclusivity (“FIE”)—FDA denied the Boehringer Petition. mL) in addition to Original Concentration Humira.”

FDA 59
article thumbnail

Bridging science and technology: a biotech CEO’s perspective

Drug Target Review

He has published several papers and two books and has twelve issued patents. He was also Vice President and Head of the Microbiome Division at Eagle Genomics Ltd, in Cambridge. Raminderpal earned his PhD in semiconductor modelling in 1997. For more: [link] ; [link] ; [link] ; Neil Wilkie, CEO, Mironid.

Science 52
article thumbnail

Analysis Life Sciences Thank You Updated guidance on promotional labeling for biosimilars and interchangeables emphasizes a similar approach

Agency IQ

It clarifies, “When multiple products are licensed as biosimilar to and interchangeable with or biosimilar to but not interchangeable with the same reference product, promotional communications should avoid representing or suggesting that any of these products (i.e., The reactions to this shift in policy were varied.